EGFR and non-small cell lung carcinoma: However, in NSCLC patients treated with one or more EGFR-TKIs, drug resistance emerges within about one year of continuous therapy in almost all cases followed by disease progression, acquired resistance develops and limits the long-term efficacy of these EGFR TKIs, leading to a lower quality of life6,7.